SNOA

Sonoma Pharmaceuticals Inc

SNOA, USA

Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and Pediacyn, an atopic dermatitis hydrogel. The company also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, it offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes, post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, a solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns, a disinfectant; and Endocyn, a root canal irrigation solution. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

https://sonomapharma.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
SNOA
stock
SNOA

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Screens Well But There Might Be A Catch simplywall.st

Read more →
SNOA
stock
SNOA

5 Healthcare Stocks On Fire This Week Benzinga

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$13.4

Analyst Picks

Strong Buy

1

Buy

0

Hold

0

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Low

1.61

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-14.10 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-3.85 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-2.53 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

2.66

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 7.40% of the total shares of Sonoma Pharmaceuticals Inc

1.

Heron Bay Capital Management

(2.0558%)

since

2025/06/30

2.

Vanguard Institutional Extnd Mkt Idx Tr

(1.1433%)

since

2025/07/31

3.

Renaissance Technologies Corp

(1.0832%)

since

2025/06/30

4.

Geode Capital Management, LLC

(1.0721%)

since

2025/06/30

5.

UBS Group AG

(0.8773%)

since

2025/06/30

6.

Fidelity Extended Market Index

(0.5402%)

since

2025/07/31

7.

Spartan Extended Market Index Pool F

(0.1878%)

since

2025/07/31

8.

Fidelity Total Market Index

(0.1538%)

since

2025/07/31

9.

Fidelity Series Total Market Index

(0.1408%)

since

2025/07/31

10.

Tower Research Capital LLC

(0.0609%)

since

2025/06/30

11.

Spartan Total Market Index Pool G

(0.0494%)

since

2025/07/31

12.

JPMorgan Chase & Co

(0.0073%)

since

2025/06/30

13.

BlackRock Inc

(0.0069%)

since

2025/06/30

14.

Northern Trust Extended Eq Market Idx

(0.0058%)

since

2025/06/30

15.

NT Ext Equity Mkt Idx Fd - L

(0.0058%)

since

2025/06/30

16.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0016%)

since

2025/06/30

17.

U.S. Bancorp

(0.0015%)

since

2025/06/30

18.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0014%)

since

2024/12/31

19.

Bank of America Corp

(0.001%)

since

2025/06/30

20.

Northern Trust Wilshire 5000

(0.001%)

since

2025/06/30

21.

NT Ext Equity Mkt Idx Fd - NL

(0.0008%)

since

2025/06/30

22.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0006%)

since

2025/06/30

23.

Morgan Stanley - Brokerage Accounts

(0.0002%)

since

2025/06/30

24.

Hanson Mcclain Inc

(0.0002%)

since

2025/06/30

25.

Quaker Wealth Management, LLC

(0.0002%)

since

2025/06/30

26.

State St US Extended Mkt Indx NL Cl C

(0.0001%)

since

2025/08/31

27.

Citigroup Inc

(0%)

since

2025/06/30

28.

Advisor Group Holdings, Inc.

(0%)

since

2025/03/31

29.

HRT FINANCIAL LLC

(0%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.32

EPS Estimate

-0.05

EPS Difference

-0.27

Surprise Percent

-540%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4.5)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.3)
GARP
Not Attractive for GARP(3)
Growth
Weak Growth Prospect(3)
Momentum
No Momentum(2.5)
Net Net
Possible Net-Net(3.5)
Quality
Low Quality Business(1.5)
Value
Fair Value(3.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.